Macaya Douoguih

机构：Johnson & Johnson (Netherlands) · ORCID：0000-0002-2707-5729

发表论文 101 篇 · 总被引 8343 次 · h-index 35

代表论文

• Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults (2023 · New England Journal of Medicine · 被引 151)
• Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study (2024 · The Lancet Infectious Diseases · 被引 27)
• Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial (2024 · Nature Communications · 被引 22)
• Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases (2024 · Nature Communications · 被引 21)
• Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults (2023 · Clinical Infectious Diseases · 被引 18)
• Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone (2023 · The Lancet Global Health · 被引 18)